Question Bank › From candidate to default

From candidate to default

From candidate to default: the company has just been placed inside buyers' own purchasing systems

Calls Tested
498
Answered YES
12
Hit Rate
2.4%
rare by design

ICL Group Ltd (ICL) — this company's answers

NO on the Q3 2022 call 2022-11-09 B+
The model's full reasoning — Q3 2022 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了公司最近从“需要说服买家考虑”转变为“已被批准、指定、列入、合格、注册、报销或预先授权”的买家采购系统内的选择,从而使得未来业务的一部分可以无需每次单独销售就能到达,并且管理层传达这种准入状态是新的,大部分量尚未反映在报告结果中。 在记录中,管理层提到了长期供应协议、合同、以及进入能源存储供应链等。但关键是要看是否有具体描述公司被纳入买方的采购、报销、规格、采购、网络、目录或计划系统,并且这种状态是新的,未来量将增加。 检查记录:管理层提到“我们签署了长期钾肥协议”、“将矿物镁业务转向长期供应协议”、“我们已签订约50%的2023-2024年产量合同”等。这些是长期合同,但长期合同本身并不一定意味着公司被纳入买方的系统,而是双方直接协议,每次订单仍需按合同执行,但合同本身是预先确定的。然而,问题要求的是“被纳入买方的采购、报销、规格、采购、网络、目录或计划系统”,即公司成为默认选项,无需每次重新论证。长期合同可能属于此类,但需要看是否描述为“新”且“大部分量尚未反映”。 管理层还提到“我们获得了美国能源部1.97亿美元的投资,用于建设锂铁磷酸盐工厂”,这属于政府资助,但并非买方系统准入。 关于“被纳入系统”的描述,记录中似乎没有明确提到公司被列入批准供应商名单、规格、报销目录等。管理层提到“我们正在将业务转向长期供应协议”,但这是公司主动行为,而非被买方系统接纳。 此外,管理层提到“我们已签订约50%的产量合同”,但这是公司自身合同,并非买方系统。 因此,没有明确证据表明公司最近获得了某种准入状态,且该状态是新的,未来量将增加。管理层只是提到长期合同和战略,但未描述具体买方系统。 所以答案应为NO。

← Back to the full ICL analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe that the company has RECENTLY crossed from being a candidate that buyers must be persuaded to consider into being an APPROVED, SPECIFIED, LISTED, QUALIFIED, REGISTERED, REIMBURSED, OR PRE-AUTHORIZED choice inside buyers' own purchasing, reimbursement, formulary, specification, procurement, network, catalog, or program systems — so that a meaningful portion of the company's future business can now arrive WITHOUT a discrete selling event for each order — AND does management convey that this access status is new enough that most of the volume it will unlock is still ahead of the reported results? Answer YES when management's own words convey this ONE phenomenon, in whatever form fits the industry: the company has moved from candidate toward default inside the routine pathway through which purchases get made. Example forms, all treated equally: being named to an approved or preferred supplier list, procurement schedule, purchasing program, or payer network; being written into specifications, standards, reference designs, configurations, protocols, or bundled defaults; being added to a formulary, reimbursement catalog, coding/payment pathway, formulary-like listing, or provider directory; being qualified onto a customer's, agency's, platform's, or program's roster; or comparable status that inserts the company into the system through which transactions routinely flow. The essential point is the EXCHANGE OF FRICTION STATUS: buying no longer has to be re-argued each time, because the company is now inside the pathway. For YES, management must also convey, directly or plainly in substance, that the status is recent and the flow through it is only beginning — so the results just reported capture little of what this access will bring. One such gateway, or several together, both qualify. Answer NO if the only access described is ordinary selling relationships, routine reseller/distribution agreements, or standard customer wins where each order still must be individually persuaded. NO if the relevant status has existed for years and is simply the company's steady way of going to market, with nothing new about the access. NO if the status is only pending, applied for, hoped for, or contingent on approvals not yet obtained. NO if management merely asserts that the product is "mission-critical," "a standard," or "the default choice" without describing a concrete buyer-side system the company has been placed into. NO if the business flowing through that status is already mature and substantially reflected in current results. NO if the access status or its significance appears only in an analyst's question that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
WRBY Warby Parker Inc. Q1 2024 2024-05-09 A
AZEK The AZEK Company Inc. Q2 2024 2024-05-08 B+
DXCM DexCom, Inc. Q4 2023 2024-02-08 B+
SCPH scPharmaceuticals Inc. Q3 2023 2023-11-08 B
INGN Inogen, Inc. Q1 2023 2023-05-05 F
HBB Hamilton Beach Brands Holding Company Q3 2022 2022-11-05 C
EVGO EVgo, Inc. Q2 2022 2022-08-09 C+
OPK OPKO Health, Inc. Q1 2022 2022-05-09 D
MGNI Magnite, Inc. Q1 2022 2022-05-04 D
AGIO Agios Pharmaceuticals, Inc. Q3 2018 2018-11-01 C
PRIM Primoris Services Corporation Q2 2018 2018-08-11 C+
IONS Ionis Pharmaceuticals, Inc. Q1 2017 2017-05-09 C

How the model reasoned

PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.

More from the question bank

Paying a named price today to serve businessEarnings outrunning the activityAnalysts converge on an emerging driverWorking harder than they are being paid forNumbers reset the ceilingDeliberately different by designAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.